Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on microglia-based treatments for neurodegenerative diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The company's management will engage in a fireside chat on February 6, 2025, at 10:30 a.m. ET.
The event will be accessible through a live webcast, for which registration is required. The presentation will also be available on the company's website in the Investors section under Events & Presentations, with the archived version remaining accessible for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL), un'azienda biotecnologica in fase clinica focalizzata su trattamenti basati sulle microglia per malattie neurodegenerative, ha annunciato la sua prossima partecipazione alla Guggenheim Securities SMID Cap Biotech Conference. La direzione dell'azienda parteciperà a una chiacchierata informale il 6 febbraio 2025, alle 10:30 ET.
L'evento sarà accessibile tramite una trasmissione web in diretta, per il quale è necessaria la registrazione. La presentazione sarà disponibile anche sul sito web dell'azienda nella sezione Investitori sotto Eventi e Presentazioni, con la versione archiviata accessibile per circa 90 giorni dopo l'evento.
Vigil Neuroscience (Nasdaq: VIGL), una empresa biotecnológica en etapa clínica centrada en tratamientos basados en microglía para enfermedades neurodegenerativas, ha anunciado su próxima participación en la Guggenheim Securities SMID Cap Biotech Conference. La dirección de la empresa participará en una charla informal el 6 de febrero de 2025, a las 10:30 a.m. ET.
El evento estará disponible a través de una transmisión en vivo, para la cual se requiere registro. La presentación también estará disponible en el sitio web de la empresa en la sección de Inversores bajo Eventos y Presentaciones, y la versión archivada permanecerá accesible durante aproximadamente 90 días después del evento.
Vigil Neuroscience (Nasdaq: VIGL), 신경퇴행성 질환을 위한 미세아교세포 기반 치료법에 집중하는 임상 단계의 생명공학 회사가 Guggenheim Securities SMID Cap Biotech Conference에 참여할 예정이라고 발표했습니다. 회사 경영진은 2025년 2월 6일 오전 10시 30분 ET에 파이어사이드 채팅에 참여할 것입니다.
이 행사는 등록이 필요한 라이브 웹캐스트를 통해 접근할 수 있습니다. 프레젠테이션은 회사 웹사이트의 투자자 섹션의 이벤트 및 프레젠테이션 아래에서도 이용 가능하며, 행사가 끝난 후 약 90일 동안 아카이브 버전이 접근 가능합니다.
Vigil Neuroscience (Nasdaq: VIGL), une entreprise de biotechnologie en phase clinique axée sur des traitements basés sur des microglies pour les maladies neurodégénératives, a annoncé sa prochaine participation à la Guggenheim Securities SMID Cap Biotech Conference. La direction de l'entreprise participera à une discussion informelle le 6 février 2025 à 10h30 ET.
L'événement sera accessible via un webinaire en direct, pour lequel une inscription est requise. La présentation sera également disponible sur le site web de l'entreprise dans la section Investisseurs sous Événements et Présentations, et la version archivée restera accessible pendant environ 90 jours après l'événement.
Vigil Neuroscience (Nasdaq: VIGL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf mikroglia-basierte Behandlungen für neurodegenerative Krankheiten konzentriert, hat bekannt gegeben, dass es an der Guggenheim Securities SMID Cap Biotech Conference teilnehmen wird. Das Management des Unternehmens wird am 6. Februar 2025 um 10:30 Uhr ET an einem Fireside Chat teilnehmen.
Die Veranstaltung wird über ein Live-Webcast zugänglich sein, für den eine Registrierung erforderlich ist. Die Präsentation wird auch auf der Unternehmenswebsite im Bereich Investoren unter Veranstaltungen und Präsentationen verfügbar sein, und die archivierte Version wird etwa 90 Tage nach der Veranstaltung zugänglich bleiben.
- None.
- None.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
To register for the live webcast, please click here. The webcast will also be available on the Company’s website in the “Investors” section under “Events & Presentations.” An archived webcast will be available for approximately 90 days following the event.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
When is Vigil Neuroscience (VIGL) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How long will the VIGL Guggenheim Conference webcast be available for viewing?
Where can investors access the VIGL Guggenheim Conference presentation webcast?
What type of presentation will VIGL deliver at the Guggenheim SMID Cap Biotech Conference?
What is the main focus of Vigil Neuroscience's (VIGL) research and development?
